RE:losing patienceI agree with the sentiment, but it is based on the 2015-16 comments not promises of the consultants who stood to gain most by an early exit.
We now know that no big pharma player was ever going to bet early on the misfolded-protein-only epitope hypothesis, not because there's anything wrong with it but because they simply don't take those kinds of risks except as developed in-house, and even in-house it's only because of internal politics. This is why Goldstein was telling early shareholders that everyone in the biz advised them to take it private.
So we're 6-years in facing a trials system designed between oligopolists and their captured regulators, and their banker-analyst echo chamber, to exclude small player competition. What Gene and Elliot attempted was probably mostly about ego and greed, but it was also audacious
and remains so.
This is why with a couple of big pharma competitors' AD programs on the ropes we need Gene to either step up or step aside. He needs to recognize that no one wants to see an AD clinical success right now more than the FDA. The window is open now to jump ship and start crediting the regulators for their recent turn-around, ignoring whatever insider politics may be behind it.
He has to know full well that at his level respect does not come from loyalty.
The share price may well remain "lacklustre" all year, it means nothing to those with patience because in the big picture things are looking pretty good.